Lundin Law PC announces it is investigating claims against Clovis
Oncology, Inc. (“Clovis” or the “Company”) (NASDAQ: CLVS) concerning
possible violations of federal securities laws. The investigation is
related to allegations that certain statements issued by Clovis were
false and misleading concerning the Company’s financial performance.
To participate in this class action lawsuit, please contact Brian
Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via e-mail at brian@lundinlawpc.com.
No class has been certified in the above action. Until a class is
certified, you are not considered represented by an attorney. You may
also choose to do nothing and be an absent class member.
The investigation concerns whether the Company violated Sections 10(b)
and 20(a) of the Securities Exchange Act of 1934. Specifically, the
investigation will focus on the Company’s November 16, 2015,
announcement that potential approval of its lung cancer treatment
rociletinib will likely be delayed.
Lundin Law PC was created by Brian Lundin, a securities litigator based
in Los Angeles.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151201006941/en/
Copyright Business Wire 2015